Grimm Lars J, Bookhout Christine E, Bentley Rex C, Jordan Sheryl G, Lawton Thomas J
Department of Radiology, Duke University, DUMC Box 3808, Durham, NC 27710, USA.
Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, 101 Manning Dr, Cb #7525, Chapel Hill, NC 27514, USA.
Clin Imaging. 2018 Sep-Oct;51:180-185. doi: 10.1016/j.clinimag.2018.04.021. Epub 2018 May 1.
Non-atypical papillomas (NAPs) diagnosed on core needle biopsy (CNB) frequently undergo surgical excision due to highly variable upstaging rates. The purpose of this study is to document our dual-institution upgrade rates of NAPs diagnosed on core needle biopsy and review the upgrade rates reported in the literature.
Following IRB approval, CNB results from Duke University (7/1/2004-6/30/2014) and the University of North Carolina Chapel Hill (1/1/04-6/30/2013) were reviewed to identify non-atypical papillomas. All cases with surgical excision or 2 years of imaging follow up were included. In addition, a literature review identified 60 published studies on upgrades of NAPs diagnosed at CNB. Cases in our cohort and the published literature were reviewed for confounding factors: [1] missing radiologic-pathologic concordance and/or discordance, [2] papillomas included with high-risk lesions, [3] high risk lesions counted as upgrades, [4] review by a nonspecialized breast pathologist, and [5] cancer incidentally detected.
Of the 388 CNBs in our dual-institution cohort, 136 (35%) patients underwent surgical excision and 252 (65%) patients had imaging follow up. After controlling for confounders, no cancers (0/388) were found at surgical excision or during follow up imaging. The literature review upstaging rate was 4.0% (166/4157) but 1.8% (4/227) after excluding studies with confounders. The combined upstaging rate from the literature and this study was 0.6% (4/615).
The upstaging rate for CNB diagnosed NAPs was 0% in our cohort and 0.6% overall after adjusting for confounders. This low rate does not warrant reflexive surgical excision and diagnostic imaging follow up should be discretionary.
因升级率差异很大,在粗针活检(CNB)中诊断出的非典型乳头状瘤(NAP)常需接受手术切除。本研究旨在记录我们双机构中在粗针活检中诊断出的NAP的升级率,并回顾文献中报道的升级率。
经机构审查委员会(IRB)批准后,对杜克大学(2004年7月1日至2014年6月30日)和北卡罗来纳大学教堂山分校(2004年1月1日至2013年6月30日)的CNB结果进行回顾,以识别非典型乳头状瘤。纳入所有接受手术切除或进行2年影像随访的病例。此外,文献回顾确定了60项关于在CNB中诊断出的NAP升级的已发表研究。对我们队列中的病例和已发表文献进行混杂因素审查:[1] 缺少放射学 - 病理学一致性和/或不一致性,[2] 与高危病变一起纳入的乳头状瘤,[3] 计为升级的高危病变,[4] 由非专业乳腺病理学家进行审查,以及[5] 偶然检测到的癌症。
在我们双机构队列的388例CNB中,136例(35%)患者接受了手术切除,252例(65%)患者进行了影像随访。在控制混杂因素后,手术切除时或随访影像期间未发现癌症(0/388)。文献回顾中的升级率为4.0%(166/4157),但排除有混杂因素的研究后为1.8%(4/227)。文献和本研究的综合升级率为0.6%(4/615)。
在我们的队列中,CNB诊断出的NAP的升级率为0%,调整混杂因素后总体升级率为0.6%。如此低的升级率不支持进行常规手术切除,诊断性影像随访应酌情进行。